NCT02537548
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
- NCT02537548 ↗
- Active, not recruiting
- University of Southern California
- Deep
We haven't built an HCP commentary report on NCT02537548 (testicular seminoma with limited retroperitoneal lymphadenopathy; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 33 indexed sources (Nov 2018 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether results apply beyond highly selected, low-volume disease
- Whether longer follow-up changes estimates of recurrence risk
- How RPLND compares with chemotherapy or radiotherapy
Also discussed: PET for nodal assessment, salvage treatment after relapse, long-term treatment toxicity.
Indexed commentary on NCT02537548 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 27 | |
| Podcasts | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
- Phase
- Phase not applicable
- Status
- Active, not recruiting
- Conditions
- Lymphadenopathy; Stage I Testicular Seminoma; Stage II Testicular Seminoma
- Interventions
- Laboratory Biomarker Analysis; Retroperitoneal Lymph Node Dissection
- Arms
- Treatment (RPLND) · Experimental
- Enrollment
- 55
- Primary outcomes
- RFS
- Sponsor
- University of Southern California with National Cancer Institute (NCI)
- Start
- Aug 28, 2015
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02537548 · updated Jun 9, 2026
Publications
linked from the registry- Hu B, Alsyouf M, Farkouh A, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black PC, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Daneshmand S. Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. J Urol. 2025 Sep;214(3):272-279. doi: 10.1097/JU.0000000000004561. Epub 2025 Apr 9. PubMed 40203124
- Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu B. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 Jun 1;41(16):3009-3018. doi: 10.1200/JCO.22.00624. Epub 2023 Mar 13. PubMed 36913642